DELEX Healthcare Group Inc. Profitable, Fast-Growing Pharma Company Revolutionizing Critical Care Meeting the Gaps in Critical Care with Innovative Pharmaceutical Solutions
Delex Healthcare Group Inc. (DELEX), a rapidly expanding pharmaceutical and healthcare company, continues to make significant strides in addressing critical care challenges. Founded in 2017 and incorporated in Delaware, USA, DELEX specializes in the development, distribution, and marketing of pharmaceutical products through its subsidiaries, including DELEX Pharma International Inc. (DELEX Pharma), DLX Holdings Corp., and JMN Brother’s Pharma Limited Inc.
BNCM / DELEX Unveils 11 New Pharmaceutical Products and Strengthens Position in Global Healthcare Market
DELEX Pharma, a global leader in pharmaceutical innovation, is intensifying its expansion efforts with the launch of 11 new pharmaceutical products and key partnerships with multinational medical device firms. This bold move underscores the company’s commitment to meeting the evolving needs of healthcare professionals and patients worldwide, while significantly enhancing its product portfolio.
DELEX Announces its Partnership with Masimo to Revolutionize Critical Care in the Philippines
DELEX Pharma International Inc. (DELEX Pharma) proudly announces its groundbreaking partnership with Masimo, a global leader in innovative noninvasive monitoring technologies, and a trusted name of intensive care unit and medical device solutions in the Philippines.
BNCM: DELEX PHARMA Bolsters Market Reach Through 6 Major Conventions in November 2024
Delex Pharma International, Inc. (Delex Pharma) strengthened its market presence in 2024 by complementing its digital initiatives, such as the ICU Forum, with participation in six major on-ground conventions, the majority of which took place in November 2024. Additionally, we have conducted hybrid webinars and events with forty-four (44) partner medical societies and hospital departments. These events target key healthcare professionals across multiple specialties, enhancing brand visibility and engagement.
BNCM Announces its Q3 and 9-Month Growth Results for 2024
BNCM has issued its Quarterly Report for the period ending September 30, 2024. On July 2, 2024, Bounce Mobile Systems, Inc. (BNCM) signed an Asset Purchase Agreement with Delex Healthcare Group, Inc. (DELEX), a Delaware-registered corporation that owns DLX Holdings, Inc., a Philippine-based company. This strategic acquisition spotlights BNCM’s commitment to expanding its portfolio and operational footprint in the healthcare sector.
BNCM: DELEX ANNOUNCE EXPANSION PLANS FOR ITS PHARMACY
The Philippines, with its population exceeding 114 million across 7,641 islands, presents a strong opportunity for growth in the pharmacy retail industry. The countrys expanding population, rising economy, and increasing incomes are driving higher demand globally for healthcare products and services.
BNCM: DELEX to Revolutionize ICU with its FDA Approved Products
DELEXs unwavering dedication to addressing the crucial needs of critical care within the healthcare landscape has intensified further and is set to propel DELEX’s growth trajectory and expand its reach ensuring enhanced accessibility to essential healthcare solutions across the country.
TIMELINE: BNCM COMPLETES MERGER WITH DELEX HEALTHCARE
October 2024. Bounce Mobile Systems Inc. (BNCM) and DELEX Healthcare Group Inc. (DELEX) have successfully completed their merger and unveiled their post-merger and management plans
BNCM: DELEX Critical Care Products Approved by the Philippine FDA
As DELEX Pharma engages in the hospital sector, it upholds the highest ethical standards for patient safety by providing a diverse range of critical care products approved by the Philippine Food and Drug Administration (FDA). This strict adherence to regulatory requirements not only ensures patient well-being but also strengthens the trust and credibility the company has built with hospitals across the country, contributing to steady product sales and revenue growth.
BNCM: DELEX Acquisition of JMN BROTHERS PHARMA will fuel its Market Growth
September 2024 DELEX Pharma International, Inc. has acquired JMN Brothers Pharma Limited, Inc. (JMN Pharma) in 2022. JMN Pharma was established in 2018 and known for its expertise in Women’s Health and Beauty, along with its ethical business in hospital products. The company is led by experienced executives from multinational pharmaceutical organizations. This strategic acquisition is projected to account for 20% of DELEX Pharma’s total corporate revenue, further strengthening its position in the over-the-counter (OTC) healthcare market.